Partnership combines AI and blockchain for healthcare
August 29, 2017
Insilico Medicine, a Baltimore-based artificial intelligence company, has announced a research collaboration with the Bitfury Group, a full-service blockchain technology conglomerate, to develop blockchain-based healthcare applications.
The companies signed a memorandum of understanding to collaborate in the academic and commercial settings to develop AI on blockchain for the healthcare industry.
"Blockchain can secure and streamline our medical systems, while AI has the potential to revitalise data management and machine learning to help identify trends and diseases," said Valery Vavilov, founder and CEO of the Bitfury Group. "By partnering with Insilico, we will be able to combine their expertise in deep learning and bioinformatics with our blockchain proficiency and real-time solutions to create bespoke and innovative new products for the healthcare sector."
Recent advances in AI have surpassed human accuracy in image and voice recognition and are transforming multiple industries, including manufacturing, transportation, finance and entertainment. However, the use of AI in the healthcare industry has been comparatively slower than in other sectors, as deep learning systems need a large number of examples to learn from and can require up to tens of millions of data sets to achieve a high level of accuracy.
Next-generation AI developed by Insilico Medicine can be used to validate, assess and improve the quality of biological samples as well as learn using large volumes of heterogeneous data without human intervention. Multiple new methodologies including the feature importance, deep feature selection and deep pathway analysis among others can provide the biologically-relevant interpretation of the inner workings of the AI systems.
Blockchain has the potential to track and validate large amounts of healthcare data in a secure and efficient ways opening the door to organise data effectively for deep learning systems. The Bitfury and Insilico partnership will explore ways blockchain can be used to accelerate progress in biomedicine and deliver innovative healthcare to people around the world.
"The Bitfury Group is one of the most reputable companies in blockchain developing their own semiconductors and end-to-end blockchain solutions trusted by the major corporations and governments worldwide," said Alex Zhavoroknov, founder and CEO of Insilico Medicine. “We are happy to enter into a research collaboration with Bitfury to develop innovative solutions that may save lives and extend human health span.”
Insilico is developing AI with the focus on deep generative adversarial networks, reinforcement learning and meta learning for drug discovery, biomarker development, cross-species analysis and aging research.